Skip to main content
Log in

Seretide withdrawal increases airway inflammation in moderate COPD patients

  • Letter to the Editors
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

References

  1. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2006. Available at: http://www.goldcopd.org

  2. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J, TORCH investigators (2007) Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 356:775–789

    Article  CAS  PubMed  Google Scholar 

  3. Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A, Anderson J, Maden C (2003) Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomized controlled trial. Lancet 361:449–456

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Zoe Borrill.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Borrill, Z., Roy, K., Kolsum, U. et al. Seretide withdrawal increases airway inflammation in moderate COPD patients. Eur J Clin Pharmacol 65, 1165–1166 (2009). https://doi.org/10.1007/s00228-009-0697-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-009-0697-5

Keywords

Navigation